NCT06634667View on ClinicalTrials.gov

Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

April 30, 2027

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

third-generation EGFR-TKI combined with anlotinib

third-generation EGFR-TKI combined with anlotinib as maintenance therapy following 4 to 6 cycles of chemotherapy and immunotherapy until progressive disease.

Trial Locations (1)

410013

Yongchang Zhang, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER

NCT06634667 - Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance | Biotech Hunter | Biotech Hunter